CBD: Difference between revisions
No edit summary |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 11: | Line 11: | ||
conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment. | conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment. | ||
=== Sativex (Nabiximols) and Glioblastoma === | |||
A Phase 1b trial investigated the combination of Sativex (nabiximols), a cannabis-based spray containing a 1:1 ratio of CBD and THC, with temozolomide (TMZ) chemotherapy in patients with recurrent glioblastoma. The study observed a significant improvement in one-year survival rates among patients treated with Sativex compared to the placebo group (83% versus 44%, respectively). This difference suggests that Sativex could enhance survival when combined with standard chemotherapy. However, researchers emphasize that these findings, while promising, need to be confirmed in larger, more robust clinical trials.<ref>{{Cite web |title=Clinical Trial: CBD | |||
Doubles Brain Cancer Survival Rates |url=https://mysupplyco.com |publisher=My Supply Co. |accessdate=2024-08-12}}</ref> | |||
=== Potential Mechanisms and Future Research === | |||
The effects of CBD in glioblastoma are thought to stem from its ability to inhibit tumor cell migration, invasion, and angiogenesis. CBD has shown potential in modulating the immune environment around the tumor, possibly enhancing the effectiveness of other treatments like chemotherapy. These preclinical findings, along with the initial clinical results, suggest a multi-targeted approach by CBD that could be beneficial in treating glioblastoma.<ref>{{Cite web |title=From bench to bedside: the application of cannabidiol in glioma |url=https://translational-medicine.biomedcentral.com |publisher=Journal of Translational Medicine |accessdate=2024-08-12}}</ref> | |||
Further research, including ongoing and future trials, is necessary to fully understand the impact of CBD and THC-based treatments on overall survival in glioblastoma patients and to determine the best protocols for their use.<ref>{{Cite web |title=Developments in cannabis-based drug trial for glioblastomas |url=https://www.thebraintumourcharity.org |publisher=The Brain Tumour Charity |accessdate=2024-08-12}}</ref> | |||
| | |||
|treatment_category=Nutraceuticals | |||
|links= | |links= | ||
|toxicity_level=2 | |toxicity_level=2 | ||
|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen. | |toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen. | ||
}} | }} | ||
Latest revision as of 10:27, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | CBD (Cannabidiol) |
| FDA Approval | Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment |
| Used for | Investigational use in cancer treatment, including symptom management and potential anti-tumor effects |
| Clinical Trial Phase | Preclinical studies and early human trials for cancer |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy |
| OS without | Not specified |
| OS with | Not applicable; ongoing research into potential impacts on overall survival in cancer patients |
| PFS without | Not specified |
| PFS with | Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen. |
Notes: CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers, conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
Sativex (Nabiximols) and Glioblastoma
A Phase 1b trial investigated the combination of Sativex (nabiximols), a cannabis-based spray containing a 1:1 ratio of CBD and THC, with temozolomide (TMZ) chemotherapy in patients with recurrent glioblastoma. The study observed a significant improvement in one-year survival rates among patients treated with Sativex compared to the placebo group (83% versus 44%, respectively). This difference suggests that Sativex could enhance survival when combined with standard chemotherapy. However, researchers emphasize that these findings, while promising, need to be confirmed in larger, more robust clinical trials.<ref>Template:Cite web</ref>
Potential Mechanisms and Future Research
The effects of CBD in glioblastoma are thought to stem from its ability to inhibit tumor cell migration, invasion, and angiogenesis. CBD has shown potential in modulating the immune environment around the tumor, possibly enhancing the effectiveness of other treatments like chemotherapy. These preclinical findings, along with the initial clinical results, suggest a multi-targeted approach by CBD that could be beneficial in treating glioblastoma.<ref>Template:Cite web</ref>
Further research, including ongoing and future trials, is necessary to fully understand the impact of CBD and THC-based treatments on overall survival in glioblastoma patients and to determine the best protocols for their use.<ref>Template:Cite web</ref>
From Ben Williams Book: Not specified
